All In Biotech

NDA 213978 · Harrow Eye

Tyrvaya

Varenicline Tartrate · Nasal

Last checked: Nov 19, 2026Latest source record: Feb 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Oct 15, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

336

68 Phase 3, 23 recruiting

FAERS reports

6,231

1,606 serious, 71 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 10, 2026.

TYRVAYA (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease. TYRVAYA (varenicline solution) nasal spray is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )

Mechanism: The efficacy of TYRVAYA in dry eye disease is believed to be the result of varenicline's activity at heteromeric sub-type(s) of the nicotinic acetylcholine (nACh) receptor where its binding produces agonist activity and activates the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease. Varenicline binds with high affinity and selectivity at human α4β2, α4α6β2, α3β4, α3α5β4 and α7 neuronal nicotinic acetylcholine receptors. The exact mechanism of action is unknown at this time.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TYRVAYA · VARENICLINE TARTRATE EQ 0.03MG BASE/SPRAY · SPRAY, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Varenicline" as an intervention, any sponsor and status, largest first.

All 336 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • sneezing749
  • nausea586
  • drug ineffective473
  • vomiting398
  • depression364
  • headache311
  • nasal discomfort263
  • product delivery mechanism issue252
  • rhinorrhoea236
  • suicidal ideation225
  • nightmare213
  • abnormal dreams212

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200768
2008839
2009478
2010187
201145
201266
201331
201433
201553
201640
201745
201851
201965
202054
202153
2022654
2023806
20241,555
2025649
2026459

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tyrvaya (Varenicline Tartrate)

2024 spending

$71.7M

Beneficiaries

28,409

90,460 claims

Per beneficiary

$2,525

$76.54 per unit

View as table
YearSpending
2020$0
2021$283,569
2022$11,557,368
2023$37,471,489
2024$71,731,632

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 603 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.